Skip to main content

Table 5 Comparison of the rate of SVR12 and adherence to DAAs

From: Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis

Reference (published year) Study design Genotype Medications Adherence assessment SVR12 (%) Adherence (%)
Present study Retrospective 1 and 2 Various kinds of DAA Pill count 99.6% (265/266) Adherent (defined as ≥95% of pill count): 99.0% (397/401)
Adherent (defined as ≥90% of pill count): 99.3% (398/401)
Retrospective analyses of clinical practice
9 (2016) Retrospective 1–3 Various kinds of DAA Patient report 93.2% (124/133) Adherent (defined as 100% of adherence): 79.1% (102/129)
12 (2017) Retrospective 1–4 Various kinds of DAA PDC from pharmacy record b Specialty pharmacy
92.9% (156/168)
Adherent (defined as ≥80% of PDC): 100% (206/206)
Nonintegrated pharmacies
88.6% (39/44)
Adherent (defined as ≥80% of PDC): 97% (55/57)
16 (2016) Retrospective 1 a SOF/LDV PDC from pharmacy record b All subjects: 95.3% (928/974)
Patients with adherence of
≥90%: 96.3% (621/645)
<90%: 95.0% (301/317)
<50%: 50.0% (6/12)
100% of PDC: 65.7% (632/962)
≥90% of PDC: 67.0% (645/962)
≥80% of PDC: 67.8% (653/962)
2 or 3 SOF+RBV PDC from pharmacy record b All subjects: 88.2% (585/663)
Patients with adherence of
≥90%: 89.9%(561/624)
<90%: 67.6% (23/34)
<50%: 20.0% (1/5)
100% of PDC: 92.1% (606/658)
≥90% of PDC: 94.8% (624/658)
≥80% of PDC: 98.3% (647/658)
17 (2016) Retrospective 1 a SOF, SOF/LDV, simeprevir Patient report 90.4% (225/249) Adherent (defined as 100% of adherence): 97.0% (360/371)
18 (2017) Retrospective 1–3 Various kinds of DAA PDC from pharmacy record b 94.1% (350/372) Mean PDC: 98.7%
Adherent (defined as ≥95% of PDC): 98.9% (358/362)
Analyses of phase 2 and/or 3 clinical trials
15 (2016) Pooled analysis of phase 2-3 studies 1–6 SOF+RBV±LDV Pill count All subjects: 84.4% (2134/2528)
Patients with adherence of
≥80%: 85.4% (1820/2131)
<80%: 79.1% (314/397)
Mean: 91.3%
Adherent (defined as ≥80% of doses): 84.3% (2131/2528)
Pooled analysis of phase 2-3 studies 1–6 SOF/LDV Pill count All subjects: 96.5% (1441/1493)
Patients with adherence of
≥80%: 97.1% (1394/1436)
<80%: 82.5% (47/57)
Mean: 97.5%
Adherent (defined as ≥80% of doses): 96.2% (1436/1493)
19 (2016) Pooled analysis of phase 3 studies 1 SOF/ LDV±RBV Pill count 96.7% (1888/1952) Adherent (defined as ≥80% of doses): 92.3% (1802/1952)
20 (2016) Pooled analysis of phase 3 studies 1–6 SOF/velpatasvir Pill count 98.1% (1015/1035) Adherent (defined as ≥90% of doses): 95.8% (992/1035)
21 (2016) Phase 2a study 1 SOF/LDV MEMS
Pill counts
Patient report
96.6% (58/60) MEMS: mean 96.7%
Pill counts: mean 98.2%
Patient report: mean 99.3%
  1. MEMS Electronic medication event monitoring system, PDC The proportion of days covered, SOF Sofosbuvir, LDV Ledipasvir, RBV Ribavirin
  2. aThe majority of the patients were infected with HCV genotype 1. Four patients were infected with genotype 4 and 175 patients were infected with an unknown genotype of HCV.
  3. bPDC was defined as the total number of days with possession of medication in a period of time